Navigation Links
An important discovery at the Montreal Heart Institute: A new approach to treat the most common heart valve disease in Western countries

Montreal, Canada, July 18, 2013 A study conducted by the team of Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute (MHI), has led to the discovery of a new approach to treat aortic valve stenosis through the administration of a compound that prevents valve deterioration and can even reverse the progression of the disease. A condition that is characterized by a narrowing of the aortic valve and that affects approximately 150,000 Canadians , aortic valve stenosis is the most common type of heart valve disease in Western countries. The results of this study were published in the British Journal of Pharmacology on July 15, 2013.

This study conducted in mice suffering from aortic valve stenosis showed successful outcomes with infusions of a compound that mimics HDL (high-density lipoprotein), which is often referred to as "good cholesterol." This treatment could help open narrowed aortic valves, avoid the major complications of aortic valve stenosis (including the need for heart surgery), and prevent heart failure and sudden death.

A less invasive option

"These results are extremely encouraging, as they allow us to hope that this type of treatment will work for people who suffer from aortic valve stenosis. If so, it will represent a brand-new treatment option that may even prevent open-heart surgery to replace valves damaged by stenosis," said Dr. Jean-Claude Tardif. "This treatment may be an alternative to a procedure that is complex, risky and very invasive for patients." Valve replacement surgery is currently the primary treatment option for this condition, with 13,000 surgeries conducted on average each year in Canada .

A growing incidence

Especially common in people over the age of 65, aortic valve stenosis can also affect people who are overweight, eat a high-fat diet, are diabetic or have a congenital abnormality. "In light of the aging of the population and alarming data on excess weight, diabetes, lifestyle and the diet of the population in general, this disease represents a major public health problem," stressed Dr. Tardif.

More details about the MHI study

In this study, mice were put on a cholesterol-enriched diet until aortic valve stenosis was detected using echocardiography (a medical imaging ultrasound system used in humans). The animals were then divided into two groups: a control group that received saline infusions and a treatment group that received infusions of a compound that mimics good cholesterol (an apoA-I mimetic peptide) for two weeks.

These results were particularly impressive as, after only 28 days of treatment, the aortic valve opened more fully in the treatment group compared to the control group. The aortic wall in the treatment group had also reduced in thickness compared to the control group.

Furthermore, microscopic analysis also revealed that the extent of the scar lesions (or accumulated collagen) in the valves was significantly smaller in the treated subjects than in the control subjects.


Contact: Lauren Guay
Montreal Heart Institute

Related medicine news :

1. US Drug Watchdog Now Calls Their DePuy Pinnacle Hip Implant Blood Test Initiative Vital And They Urge Recipients To Call Them For Instructions About This Important Test
2. New Mirena IUD Complications Lawsuits Allegations Report: Resource4thePeople Reports Important Multidistrict Litigation Hearing Scheduled
3. Neurosurgery publishes findings of 3 important studies in June issue
4. Dr. Kanani, Woodland Hills Dentist: Tongue Brushing May Be as Important as Tooth Brushing
5. Latest Pradaxa Internal Bleeding Problem Allegation Lawsuits Update; Resource4thePeople Reports Judge Schedules Important Hearing
6. Alleged NuvaRing Blood-Clotting Lawsuits Update: Resource4thePeople Reports Important Hearing Scheduled for July
7. Alleged Zoloft Birth Defects Lawsuits Report from Resource4thePeople: Federal Judge Schedules Important Status Conference
8. Medical Practice Management Important as Aging Baby Boomers and Affordable Care Act Expand Pool of Patients: Appointment-Plus
9. Jean LaMantia Registered Dietitian, Cancer Survivor and Author Announces An Important Partnership to Help Put a Much-Needed Resource Into the Hands of Cancer Patients Across the Nation
10. Researchers take important step in unlocking what causes congenital heart disease
11. Scott Tischler of Tischler Brothers Fitness unveils the 8 reasons why water is so important
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: